RESUMEN
BACKGROUND: The Skvortsov Herbarium of the Tsitsin Main Botanical Garden, Russian Academy of Sciences (MHA) in the 1945-1980s dealt with vascular plants and only scattered occasional collections of bryophytes and lichens were accumulated there without special arrangement. Since the late 1980s, the bryophyte studies in the MHA Herbarium became permanent and several projects were started since then, including the currently conducted "Moss Flora of Russia". There are many white spots on the map of bryophyte exploration of Russia, but one of the most conspicuous was Yakutia, the largest administrative unit of Russia, covering 3,081,000 km2. Yana-Indigirka Region, originally defined as a floristic region, includes Verkhoyansky Range and some smaller adjacent mountain areas. It is the largest amongst the bryofloristic regions in Russia, but exploration of its territory, which is difficult to access, remains far from complete. NEW INFORMATION: Several expeditions of the Institute for Biological Problems of Cryolithozone, Siberian Branch of Russian Academy of Sciences, and the Main Botanical Garden, Russian Academy of Sciences in 2000-2018 yielded in many bryophyte specimens, partly published in a number of papers. This dataset comprehensively represents the diversity of mosses of the Region. It includes 7,738 records of moss specimens preserved in the MHA Herbarium.
RESUMEN
BACKGROUND: The registry is the main source of information about patients with acromegaly for assessing the quality of medical care, effectiveness of treatment, determining the compliance of real clinical practice with existing standards and patient management protocols. AIMS: To evaluate epidemiological, demographic and clinical characteristics of acromegaly in Russian Federation and effectiveness of treatment modalities. MATERIALS AND METHODS: The object of the study was the database of the united Russian registry of patients with pituitary tumors with specific analysis of patients with acromegaly only. We analyzed the data of 4114 patients with acromegaly stored on the online system in February 2019. RESULTS: Based on the data 32% of patients had complete clinical and laboratory remission of acromegaly; the percentage of patients with no remission was 68%, among them 22.5% had significant improvements in clinical symptoms and a decrease in growth hormone (GH) and insulin-like growth factor-1 (IGF-1) without IGF-1 normalization. The average age of patients at the onset of the disease was 42.7 years and at diagnosis – 45.8 years. The ratio of men to women was 1:2.6. In patients with acromegaly hypopituitarism was registered in 14.7% of cases and among them hypothyroidism (66%) and hypogonadism (52%) were registered more often. Among other complications the leading were diabetes mellitus (15.7%) and acromegalic arthropathy (15%). The proportion of patients receiving neurosurgical treatment increased from 35.7% to 49.6% in 2012–2019; the portion of patients undergoing radiation therapy decreased significantly from 17.7% in 2012 to 0.8% in 2019. Remission was achieved in 40.47% after neurosurgery and 28.95% after medical treatment as a first line therapy p<0.01. The number of patients receiving medical treatment at the time of the study was 1209. Among them 51% of patients treated with long-acting lanreotide and 24% receiving long-acting octreotide achieved remission (p<0.0001) CONCLUSIONS: The remission rate of acromegaly remains suboptimal despite increased surgical activity, which corresponds to global trends. Long-acting lanreotide was significantly superior versus long-acting octreotide in the rate of acromegaly remission, which does not correspond with clinical trials.